A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin
Completed · Phase 3 · NCT05275400
Conditions: Type 2 Diabetes
At a glance
- Research payments reported, 2025
- $32,627
- U.S. investigators named
- 11
- Sites paid
- 11
- Planned or actual enrollment
- 986
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Insulin Efsitora Alfa (drug), Insulin Degludec (drug)
- Dates
- Started 2022-03-08; completion 2024-05-15
- Results posted
- Yes
The reason for this study is to see if the study drug insulin efsitora alfa (LY3209590) is safe and effective in participants with Type 2 diabetes that have already been treated with basal insulin. The study consists of a 3-week screening/lead-in period, a 78-week treatment period and a 5-week safety follow-up period. The study will last up to 86 weeks.
From ClinicalTrials.gov, last updated 2025-06-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $32,627 in research payments for this study in 2025 (13 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Timothy S. Bailey, M.D. Endocrinology & Diabetes · Escondido, CA
- Anna R. Chang, M.D. Internal Medicine · Concord, CA
- Anuj Bhargava, MD Endocrinology & Diabetes · West Des Moines, IA
- Helena W. Rodbard, M.D. Endocrinology & Diabetes · Rockville, MD
- Richard M. Bergenstal, MD Endocrinology & Diabetes · St Louis Park, MN
- Ralph J. Duda JR., M.D. Endocrinology & Diabetes · Springfield, MO
- Demetri W. Marshall, M.D. Family Medicine · Port Gibson, MS
- Anastasios Manessis, MD Endocrinology & Diabetes · New York, NY
- Samir Arora, M.D. Specialist · Powell, OH
- Lisa B. Connery, M.D. Family Medicine · Norman, OK
- Hien T. Tran, MD Endocrinology & Diabetes · Round Rock, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sky Clinical Research Network Group $14,775
- Cr Services Acquisition US LLC $5,295
- Clinvest Research LLC $4,674
- John Muir Med Fndtn DBA John Muir Phys Network $4,338
- Headlands Research California LLC $1,340
- Healthpartners Institute for Education $1,203
- Alliance for Multispecialty Research Lls $411
- Texas Diabetes and Endocrinology PA $241
- Iowa Diabetes and Endocrinology Rsrch Cntr $200
- Helena W Rodbard, MD, PA $85
- Nyc Research Inc $65
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.